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‘Nanomedicine’, the application of nanotechnology principles to the field of
medicine, has stimulated the development of nano-platforms for next generation drug
delivery. By exploiting nanoscale properties of materials to selectively alter intrinsic
characteristics of therapeutics, researchers have improved the efficacy and
pharmacokinetic profiles for a variety of drug types. Despite preliminary commercial and
clinical success, there still remains a need to develop an improved delivery platform that
can provide high cargo entrapment, efficient intracellular delivery, evasion of
intracellular degradation pathways, and provide cell population specific targeting.
In this study we engineered a nanocarrier system composed of a core bilayer
structure of biocompatible lipids and cholesterol, and an exterior surface coating of
hyaluronic acid (HA). We optimized both the HA crosslinking reaction to the
nanoparticle surface (HA-LNP), as well as the rehydration and entrapment conditions for
optimal encapsulation efficiency. The HA-LNP system promoted uptake of an
impermeable fluorescent model cargo as well as increased the therapeutic index of
Doxorubicin by over 30 % compared to the free form counterpart. Confocal microscopy

was used to probe the endolysomal fate of HA-LNPs in cardiac, brain, and breast cells
leading to validation of cell-dependent cytoplasmic distributions of the nanocarrier
system with minimal lysosomal co-localization.
In order to investigate the effect of stiffness on nanoparticle uptake, we created
2D gel substrates with physiologically relevant stiffness ranging from 2kPa to 70 kPa.
Flow cytometry was used to quantify HA-LNP uptake as a function of time and substrate
stiffness in metastatic breast cancer cells. Interestingly we observed an initial preferential
uptake mechanisms with cells on soft substrates both per cell and population wide,
however at later time points we found that the overall capacity for HA-LNP uptake
between all the substrates is equivalent, signifying the stiffness effect on HA-LNP uptake
is transient. Further analysis of this mechanism could lead to the development of drug
delivery platforms with increased intracellular delivery efficiency and specificity.
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CHAPTER 1 INTRODUCTION
1.1. Overview and Significance of Problem
The ability to control the spatial distribution and residence time profile of a
therapeutic drug is a paramount goal and current hurdle for both biomedical engineering
and the pharmaceutical sciences. In general, the vast majority of therapeutics utilized to
treat a specific condition or ailment are employed in their “naked”, non-altered, state.
Since the human body is efficient at the identification and subsequent removal of foreign
material, maximum tolerable doses commonly must be implemented in order to achieve
an appreciable drug concentration at the site of interest. This mandatory high dosage
regimen may ultimately lead to offsite toxic effects to various organ systems, induce
potential host adaptation/resistance, restrict the types of drugs that can be used for
therapeutic purposes, and impose a monetary burden for both drug research and
development as well as treatment options for the consumer. In addition to high dosage
concerns, naked administration of therapeutics is also limited in efficacy due to systemic
attenuation, rapid clearance from the body, unfavorable intracellular delivery and
population specificity, and potential for instigation of an immune response. Thus, there is
a dramatic need for the development of novel methods and materials for the improvement
in the transport of therapeutics cargo.
In order to address the limitations and potential toxicity of naked therapeutics,
principles of nanotechnology have been applied to create novel platforms for next
generation delivery systems. This hybrid field, termed Nanomedicine, exploits the
nanoscale properties of materials to selectively alter the intrinsic characteristics of bare
therapeutics such as solubility, diffusivity, half-life, biodistribution, and release kinetics
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[1] to acquire enhanced drug pharmacokinetic profiles [2]. While Nanomedicine as a
whole includes entities spanning from nanofibers to nanoscaffolds, nanoparticles have
played a paramount role in advancing the nanoscale delivery of therapeutics. However,
there is a need for the ability to deliver a range of different therapeutics with a single
nanocarrier platform. The current single purpose- single nanoparticle platform ideology
has greatly slowed the movement of robust drug delivery systems into both clinical trials
and to market.

1.2. Background
1.2.1. Need for Improved Nanoparticle Systems for Therapeutic Delivery
Nanoparticle based drug delivery platforms operate on the same scale as biological
systems, and therefore are ideal for the intracellular delivery of therapeutic cargo for the
treatment of disease. To date, numerous drug delivery systems have been developed
including gold nanoparticles [3], lipid vesicles [4], and protein based nanocarrier systems
[5] amongst others. The central goal of these nanoparticle drug delivery systems is to
capture, protect, and successfully deliver a therapeutic cargo to a specific coordinate in
the body. However, there currently lacks a versatile, yet translatable, platform that can
deliver a variety of therapeutic cargo types and sizes via a scale up friendly process for
broad disease management.
1.2.2. Discovery of Liposomes
Liposomes are spherical vesicles of ~100 nm diameter consisting of a lipid bilayer
shell and an aqueous core held together by amphipathic molecule driven stabilization.
This structure was discovered by Alec Bangham and coworkers in the mid-1960s [6, 7],
and has since been the standard model system for biological membranes [8]. Liposomes
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are comprised principally from phospholipids and cholesterol, but can also obtain other
components with favorable amphipathic properties. Upon contact with water, lipid
molecules will self-assemble into three dimensional structures as a function of
thermodynamics, interaction free energies, and geometry between the polar head group
and nonpolar tail (s) [9]. Many methods have been studied to create monodisperse
populations of liposomes including agitation (sonication), mechanical extrusion, solvent
dispersion, and detergent removal [10]. The precise method that should be used is
dependent upon the final application of the particles, the physicochemical properties of
the specific lipids, and the potential for scale up.
1.2.3. Liposome Application in Drug Delivery
Liposomes are extremely versatile nanocarriers that have been studied and utilized
extensively for drug delivery applications due to their ease of creation, large protective
hydrophilic inner cavity for encapsulation, and controllable drug release kinetics. As a
result of unique bilayer structure, liposomes are able to efficiently encapsulate and
improve the pharmacokinetics of both hydrophobic and hydrophilic cargo. Furthermore,
liposomes can be tailored for specific applications by either structural based changes such
as overall particle size and extent of membrane fluidity, and also by altering their surface
characteristics such as charge, steric effect (hydration), and targeting potential. This high
degree of freedom of exterior customization has been utilized to create long circulating
“stealth” liposomes [11], as well as liposomes that can target specific cell populations via
active targeting means [12-15].
Currently, over 15 liposome and lipid based drug formulations are approved for
clinical use, with over 600 additional clinical trials in progress [11, 16-18]. These
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formulations span treatment areas ranging from cancer and preventive vaccination to
microbes and hormone replacement. However, each of these delivery formulations is
constrained to a specific cargo type and subsequently a pre-determined function.
Consequently, there remains a need for a lipid based platform capable of delivery of a
variety of cargo types with high encapsulation, favorable intracellular delivery, and
potential for industrial scale up to catalyze the commercialization of next generation drug
delivery systems.

1.3. Thesis Outline
This thesis focuses on developing a lipid nanoparticle system for advanced drug
delivery applications and is subdivided as follows: Chapter 2 described the optimization
steps in nanoparticle fabrication and optimal cargo entrapment. In addition, Chapter 2
goes over through characterization of the nanocarrier system and also tests the overall
stability of the particles. Chapter 3 probes the potential of the nanocarrier system to
undergo efficient intracellular delivery. Specifically, Chapter 3 investigates the delivery
of a range of different model therapeutics in breast, brain, and cardiac cells. Chapter 3
also probes the endolysosomal fate of the nanocarrier system in all three cell types.
Chapter 4 describes the investigation of the effect of substrate stiffness on nanoparticle
uptake in cancer cells, and discusses how this information can be used to create next
generation drug delivery systems with increased population targeting specificity. Chapter
5 concludes the thesis with goals and suggestions for future work with the
aforementioned nanocarrier system.
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CHAPTER 2: DEVELOPMENT OF A LIPID BASED
NANOCARRIER SYSTEM CAPABLE OF HIGH
ENTRAPMENT OF THERAPEUTIC CARGO
2.1. Introduction
The ambition to safely and reproducibly transport a therapeutic cargo to a specific
coordinate of the body is a main catalyst for the development of next generation
advanced drug delivery systems. Both bare and surface functionalized liposomes, termed
lipid nanoparticles (LNPs), have been used to successfully circumvent non-ideal
characteristics of therapeutic drugs leading to 1) significant improvement in half-life in
vivo and 2) reduction in systemic toxicity prompting potent improvement in therapeutic
index [19, 20]. However, the initial step of cargo entrapment has remained a main hurdle
for the implementation of lipid based drug delivery systems.
In order to successfully deliver a hydrophilic drug, liposomes must first encapsulate
the cargo into either the aqueous interior of the nanoparticle. This entrapment procedure
can be performed either passively, during liposome formation, or actively, post liposome
formation. Passive entrapment of hydrophilic cargo requires addition of the drug into the
rehydration medium of the initial dry lipid film encouraging entrapment during primary
vesicle formation. This procedure leads to low entrapment efficiencies due to the small
internal volumes of the nanoparticles as compared to the bulk solution [21]. In addition,
since the drug is introduced early in the liposome formation process, appreciable drug
degradation is possible during subsequent processing steps.
Active mechanisms for hydrophilic drug loading into liposomes includes pH gradient
loading [22], temporary liposome and/or drug permeabilization [23], and the
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lyophilization and rehydration method [24-27]. While all three active loading approaches
lead to drug entrapment post liposome formation, the lyophilization and rehydration
technique has many advantages over the other two methods. The lyophilization and
rehydration method involves forming liposomes in drug-free physiological buffers,
followed by a quick snap freeze and a subsequent highly controlled freeze dry step to
achieve a dry lipid film. During this freeze dry process the liposome is gently lowered out
of solution and when the driving force for self-assembly is critically reduced, the
nanoparticle will open up into a lipid bilayer sheet and adhere to the bottom of the
container. Upon careful rehydration, the dry lipid film will swell and spontaneously reform into a liposome via interaction with and entrapment of local solution. By adding
drug into this rehydration medium, high drug entrapment has been achieved [26, 28].
A significant hurdle for widespread implementation of the lyophilization and
rehydration procedure is vesicle fusion upon rehydration. Without a lyoprotectant added
to the liposome containing solution prior to snap freezing, such as the disaccharide
trehalose, appreciable vesicle fusion occurs during the rehydration step yielding micro
scale particles impractical for drug delivery purposes. To evade the use of free sugar
molecules, the synthetic polymer polyethylene glycol (PEG) [29] or naturally derived
extracellular matrix protein such as hyaluronic acid (HA) [30-33] have been covalently
cross linked to the liposome surface prior to lyophilization to act as steric barriers during
the rehydration step. However, there is currently a need to develop an actively loaded
liposome delivery system capable of efficient entrapment of a range of therapeutic sizes
and long term stability in solution with a potential for scale up.
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Herein, we have engineered a lipid nanoparticle system comprised of a core structure
of biocompatible lipids and cholesterol, and a surface decorate of high MW HA. We
optimized both the HA crosslinking reaction to the nanoparticle surface, as well as the
rehydration and entrapment conditions for optimal entrapment efficiency. We modeled a
range of therapeutic entrapment by utilizing the fluorescently tagged model drugs: 1) 20
kDa FITC tagged Dextran (20 kDa FD) – model drug for silencing RNA entrapment, 2)
70 kDa FITC tagged Dextran (70 kDa FD) – model drug for protein based therapeutics,
and 3) Doxorubicin (DOX) – model drug for small molecule inhibitors and
chemotherapeutics.

2.2. Materials and Methods
2.2.1. Preparation of the LNPs
Multilamellar vesicles (MLV) composed of L α-Phosphatidylcholine (PC) (Avanti
Polar Lipids), 1, 2- Dipalmitoyl-sn-Glycero-3-Phopshoethanolamine (DPPE), and
Cholesterol (CHOL) (both from Sigma Aldrich) were created via the traditional dry film
method as previously reported [14, 28, 30, 31, 33, 34]. This MLV solution was allowed
to rest overnight at 4°C, and the next day was mechanically extruded using an Mini
Extruder Apparatus (Avanti Polar Lipids) maintained at 65-70 °C in a stepwise fashion
with progressively smaller membrane pore sizes to reach a final unilamellar vesicle
(ULV) in the size range of 80-100 nm hydrodynamic diameter. Each membrane size
underwent numerous cycles to ensure final product homogeneity.
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2.2.2. Surface Modification of LNPs with Hyaluronic Acid and the
Lyophilization Process
Hyaluronic Acid (HA), ~1.65 MDa (Sigma) was dissolved in Sodium Acetate Buffer
(pH 5) to a final concentration of 2 mg/ml. The HA was activated in solution with 1ethyl-3-(3-dimethylaminopropyl) carbomiide (EDAC) (Sigma) at a mass ratio of 1:20
respectively via gentle mixing at 37°C (pH ~4) for 2 hours [35]. The post extrusion
LNPs were separated from lipid debris by ultracentrifugation (140,000 g, 4°C, 1.5 hr.)
followed by rehydrating the pellet in 0.1M Borate Buffer (pH 8.6). The activated HA
solution was combined with the purified LNP solution and incubated for 24 hours at
37°C (pH 8.6) with gentle mixing to mediate amide bond formation. Separation of the
resulting HA-LNP from excess reagents in solution was achieved by washing three times
using ultracentrifugation. Following purification, the particles were aliquoted, snap
frozen, and lyophilized for 60 hrs. using a Chamber Freeze Dry System (Labconco) [31].
The lyophilized particles were stored at -80 °C until use.
2.2.3. Rehydration (Entrapment) protocol and Cargo Encapsulation
Quantification
The lyophilized HA-LNP particles were rehydrated with 1/10th of the original solute
volume composed of nuclease free water containing the cargo (FITC-Dextran or
Doxorubicin), followed by quick vortex agitation to ensure the full quantity of
lyophilized powder was hydrated. After total rehydration the mixture was left to rest for
30 minutes to allow for lipid membrane re-assembly. Following this rest period, PBS
solution was added to the sample to match the initial pre-lyophilization volume and unencapsulated drug was removed by ultracentrifugation (140,000 g, 4°C, and 1.25 hr.). For
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encapsulation efficiency determination of the FITC tagged Dextran (FD) (Sigma) cargo,
fluorescence at 495 nm em/ 520 em was measured in the presence of 0.1 % Triton X-100
detergent to disrupt the lipid bilayers. With a known amount of fluorescent drug present
during the entrapment procedure, a standard curve was utilized to determine the amount
entrapped. The analogous procedure was performed to determine the encapsulation
efficiency of Doxorubicin (Sigma) using the natural fluorescence of the chemotherapeutic
(ex. 470 nm, em. 585 nm).
2.2.4. Particle Size Distribution, Hydrodynamic Diameter, and Zeta
Potential Analysis
Particle size distribution, mean diameter, and zeta potential were measured using a
NanoBrook ZetaPALS zeta potential and dynamic light scattering instrument
(Brookhaven). The particle size distribution and mean hydrodynamic diameter was
analyzed as both intensity and volume averaged distributions using a scattering angle of
90°. The Smoluchowki model was utilized to calculate the zeta potential from mobility
measurements. All measurements were performed in 0.05x PBS (pH 7.4) at 25 deg C.
2.2.5. Transmission Electron Microscopy (TEM)
The phosphotungstic negative stain method was utilized for visualization of the LNP
system. A drop of each sample (HA-LNP, HA-LNP-70 kDa FD, LNP Pre-Lyophilization,
and LNP Post-Lyophilization) was applied to separate copper grids coated with a carbon
film and left to air dry. A 2% phosphotungstic acid solution was applied for negative
staining, and the samples were analyzed in the UNL Microscopy Core Research
Facility’s TEM (Hitachi H7500).
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2.3. Results and Discussion
2.3.1. Lipid Nanoparticle System Characterization
To develop a nanocarrier system capable of high cargo entrapment efficiency for a
range of therapeutic sizes and long term stability in solution, we first engineered highly
customizable LNPs as described in Fig 2.1. The LNPs were composed of the natural/
biocompatible lipids PC and DPPE in combination with cholesterol, and had a mean
particle size of 93.6 ± 0.4 nm, a polydispersity index of 0.061, and a slightly negative
surface charge of -9.46 ± 0.31 mV as measured by DLS and a Zeta Potential Analyzer. To
successfully surface decorate the LNPs with high MW Hyaluronic Acid (HA), crosslinking
optimization between the primary amine of DPPE and the carboxyl group of HA was
performed to ensure effective surface functionalization under conditions that limit the
formation of large aggregate structures (Fig 2.2). Specifically, a ratio of 65 μg HA/ μmole
lipid during the reaction procedure was found to be the ideal condition for single
nanoparticle-HA amide bond construction, leading to the formation of a monodisperse
population of HA coated LNPs. Following this DPPE-HA crosslinking procedure, the
mean particle size increased to 157.2 ± 1.2 nm, a polydispersity index of 0.105, and a
moderately negative surface charge of -38.07 ± 0.35 mV due to the presence of HA’s
charged carboxyl groups.
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Figure 2. 1. Lipid nanoparticle (LNP) fabrication overview schematic.

A

B

Figure 2. 2. Optimization of the Hyaluronic Acid (HA) crosslinking reaction to the
surface of the LNPs. Change in nanoparticle diameter (A) and surface charge (B) as a
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function of amide bond formation between the primary amine of the DPPE lipid and the
carboxyl group of HA.

Following the lyophilization process and subsequent rehydration in the presence of
physiological buffer, the HA-LNPs particle size increased minimally and underwent no
significant change in net surface charge indicating that all HA remained on the outside of
each particle during the bilayer reformation process. This step was crucial to ensure that
the HA-LNPs would not be structurally altered during the entrapment procedure.
Next, we wanted to study the rehydration of the HA-LNPs in the presence of a model
drug molecule, FITC-tagged Dextran (FD), to optimize drug entrapment conditions. A
range of molecular weight FD (10, 20, and 70 kDa) was successfully encapsulated and used
to demonstrate that the diameter of the HA-LNP carrier post drug entrapment is not a
function of the size of the cargo in the aqueous interior of the nanoparticle, as well as the
versatility of the carrier to entrap a broad range of cargo sizes. The chemotherapeutic
Doxorubicin (DOX) was also successfully encapsulated in an analogous manner with
additional precautions taken to avert degradation. Comprehensive data on particle size,
surface charge, and cargo entrapment is located in Table 2.1. Particle size distributions of
the nanoparticle systems HA-LNP, HA-LNP-FD (10, 20, and 70 kDa), and HA-LNP-DOX
were also probed to confirm that in each case a monodisperse population of particles was
obtained (Fig 2.3).

G(s): % Light Scattering Intensity
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Figure 2. 3. Particle Size distribution information of the nanoparticle systems.
Table 2. 1. Dynamic Light Scattering, Electrokinetic Potential, and Drug
Encapsulation Analysis of the Nanoparticle Systems.
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2.3.2. Nanoparticle Stability
We next investigated the nanoparticle stability in solution over 90 days. As a result of
the increased surface charge density of the LNPs following HA surface crosslinking, the
interactions between the particles in suspension were now outside the thermodynamic
confines of colloidal instability (~|35|mV) [36], yielding a long-term stable nanoparticle
suspension. Hyaluronic Acid coated LNPs were validated to be stable and avert bilayer
fusion for over three months at 4° Celsius (Table 2.2).
Table 2. 2. HA coated nanoparticle stability as a function of time. Stability was
assessed by changes in particle diameter and surface charge. The HA-LNPs were stored
in 4°C during the test.

2.3.3. Analysis of Cargo entrapment (20, 70 kDa FD) and DOX
To test the ability of the HA-LNP nanocarrier system to entrap a range of different
therapeutic types, three model drugs were implemented: DOX (0.58 kDa), 20 kDa FITC
tagged Dextran (FD), and 70 kDa FD. Following rehydration of the dry lipid powder, an
encapsulation efficacy of 65%, 55%, and 35% for the DOX, 20 kDa FD, and 70 kDa FD
was achieved respectively (Table 2.1). The decrease in encapsulation efficiency as the
therapeutic cargo size increases was expected due to the increased steric force of
therapeutic confinement in the aqueous core of the nanoparticle.
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2.3.4.

TEM

Transmission electron microscopy was used to characterize the nanocarrier on a per
particle basis. TEM characterization of the LNP system exposed that 1) the surface
roughness increased post crosslinking to HA, further providing validation of an
appreciable coating of the biopolymer on the nanoparticle surface, and 2) that HA is an
effective cryoprotectant for LNPs and is required to keep the nano-dimensions of the
platform during the drug entrapment process (Fig 2.4).

Figure 2. 4. Transmission Electron Microscopy (TEM) using the negative stain method
with 2% phosphotungstic acid. Scale Bars are 250 nm for TEM.

2.4. Conclusions
The commercialization of advanced drug delivery systems has been hindered due to
the fabrication of single purpose platforms. While liposomes and lipid based
nanoparticles have been used to improve the efficacy of therapeutic drugs, there still
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remains a need for the development of a single nanocarrier system that can be used to
successfully encapsulate a range of therapeutic types for broad applications with a high
potential for scale up. In this study we engineered a lipid nanoparticle system comprised
of a core structure of biocompatible lipids and cholesterol, and a surface decorate of high
MW HA. We optimized both the HA crosslinking reaction to the nanoparticle surface, as
well as the rehydration and entrapment conditions for optimal entrapment efficiency. We
modeled a range of therapeutic entrapment by utilizing the fluorescently tagged model
drugs: 1) 20 kDa FITC tagged Dextran (20 kDa FD) – model drug for silencing RNA
entrapment, 2) 70 kDa FITC tagged Dextran (70 kDa FD) – model drug for protein based
therapeutics, and 3) Doxorubicin (DOX) – model drug for small molecule inhibitors and
chemotherapeutics.
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CHAPTER 3: INTRACELLULAR DELIVERY OF
THERAPEUTICS TO CARDIAC, BRAIN, AND BREAST
CELLS VIA THE LIPID NANOPARTICLE SYSTEM
3.1. Introduction
The principal objective of a nanoparticle drug delivery system is to capture, protect,
and successfully transport a therapeutic cargo to a specific coordinate in the body. During
this process, the nanocarrier system must overcome numerous extracellular and
intracellular barriers to facilitate the designed function of the therapeutic. In recent years,
there has been a significant interest in developing novel drug delivery systems that can
successfully promote efficient intracellular delivery of therapeutic cargo, and also evade
cellular degradation pathways such as lyosomal entrapment to promote increased drug
efficacy [37, 38].
Lipid based nanoparticle (LNP) systems have been successfully employed to mediate
intracellular delivery for a variety of therapeutics including protein [39], nucleic acid
[40], and small molecule chemotherapeutics [14, 22] amongst others following systemic
administration. However, by increasing the circulation time of LNPs via surface coating
with polyethylene glycol (PEG) to create stealth particles, studies have seen a marked
decrease in cellular uptake efficiency [41]. In addition, since PEG does not favor a
specific endocytosis pathway over another, this process cannot be altered to influence the
endolysosomal fate of the LNP system. Therefore there is a need to develop a drug
delivery platform that mediates efficient intracellular delivery of a range of therapeutics
types that can also escape lysosomal degradation and distribute the therapeutic
homogenously throughout the cytoplasm.
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Herin, we have tested and optimized our previously engineered high MW Hyaluronic
Acid (HA) coated LNP system to promote intracellular delivery of therapeutic cargo and
evade lysosomal degradation in cardiac, brain, and breast cells in vitro. The HA-LNP
system promoted uptake of a cell impermeable fluorescent model cargo, FITC-dextran, as
compared to the naked form. Furthermore, the HA-LNP system increased the therapeutic
index of Doxorubicin by over 30 % compared to the free form of the drug to metastatic
breast cancer cells. Confocal microscopy was used to probe the endolysomal fate of HALNPs in cardiac, brain, and breast cells leading to validation of cell-dependent
cytoplasmic distributions of the nanocarrier system.

3.2. Materials and Methods
3.2.1. Cell Culture Protocol
21MT-1 Cells were a kind gift from Dr. Band at the University of Nebraska Medical
Center. This cell line was isolated from the metastatic pleural effusion mammary tumor
specimens [42]. The 21MT-1 cells were cultured in α-MEM media supplemented with 5%
fetal bovine serum (FBS), 1% Penicillin-Streptomycin (PS), 1% L-glutamine, 20 mM
HEPES, non-essential amino acids, sodium pyruvate (all stated reagents from Invitrogen),
12.5 ng/ml epidermal growth factor (EGF) and 1µg/ml hydrocortisone (both from Sigma).
SKBR3 (ATCC HTB30), a human HER2+ invasive mammary gland adenocarcinoma cell
line, were cultured in analogous conditions as the 21MT-1 cells except without the addition
of EGF or hydrocortisone. MCF10A (ATCC CRL-10317), human normal breast tissue cell
line, were cultured in DMEM/F12 (Mediatech) and supplemented with 1% L-glutamine, 1
% Penicillin-Streptomycin, 5% Horse Serum, 0.1 ng/ml cholera toxin (Sigma), 0.5 µg/ml
hydrocortisone, 10 µg/ml insulin (Sigma), and 0.02 ng/ µl rhEGF (Sigma). HL1 mouse
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cardiomyocytes were a kind gift from Dr. Mishra at University of Nebraska-Medical
Center (UNMC) and grown in Claycomb Media (Sigma) supplemented with 5 % FBS, 1
% PS, 0.1 mM Norepinephrine (Sigma), and 0.1 mM L-glutamine (Sigma). A172 human
glioblastoma cell line (ATCC CRL-1620) were cultured in DMEM (Sigma) media
supplemented with 10% FBS and 1 % PS. Primary cerebellum astrocytes were a kind gift
from Mrs. Christina Wilson, and cultured in DMEM media supplemented with 10% FBS
and 1 % PS. For all cell types, the inclusion of FBS signifies the term “complete media”,
while the absence of FBS from the media is called “incomplete media”. All cells were kept
in aseptic conditions, and grown in an incubator at 37°C and 5 % CO2.
3.2.2. Therapeutic Cargo Uptake Experiments
21MT-1, SKBR3, MCF10A, and HL1 cells were plated in 12 well plates at a seeding
density of 100,000 cells/ well and left overnight in complete media to facilitate cell
attachment. The next morning the media was switched to incomplete media and 70 pmol
of 20 or 70 kDa FD either encapsulated inside HA-LNPs or in the naked form (no
nanocarrier) was added to designated wells. After a 5 hour incubation time, the cells were
washed three times with 1X PBS followed by visualization with a fluorescent microscope
and quantification of FD uptake by a fluorescent plate reader. Both the HA-LNP-FD and
naked FD samples were compared to control cells with no FD added to remove specific
cell auto-fluorescence.
3.2.3.

Flow Cytometry

Flow cytometry was performed using a FACSCantoII (BD). Two 12 well plates plated
with 100,000 A172 or primary cerebellum astrocyte cells/well was cultured overnight
within complete media. The media was switched to incomplete media, and select wells
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were cultured with 85 μg/well of fluorescently conjugated HA-LNPs (fluorescently tagged
cholesterol) for 12 hours. Following the incubation time, cells were washed three times
with sterile 1X PBS, trypsinized, transferred to flow cytometry tubes, and analyzed for
fluorescence in the green channel (ex. 495, em. 520; 10,000 total events/read) against
control cells.
3.2.4. Confocal Microscopy
Two separate experiments were performed using live cell confocal microscopy: 1)
intracellular delivery of 20 kDa FD by HA-LNPs to 21MT-1 cells and 2) analysis of the
intracellular fate of the HA-LNPs following endocytosis in 21MT-1, A172, primary
astrocytes, and HL1 cardiomyocytes. In both cases, the cells were all plated to 80 %
confluency on 35mm glass bottom dishes (Mattek). The first experiment followed
analogous procedures described earlier involving cellular incubation with 165 pmol of 20
kDa FD encapsulated inside HA-LNPs for five hours. The second experiment employed
the usage of HA-LNPs tagged with 0.15 mass % Top Fluor Cholesterol (Avanti) in the
lipid bilayer as a tracker, a five hour incubation of the tagged particles with 21MT-1 cells,
and lysosome staining by Lysotracker Red DND 99 (Life Technologies) . In both
experiments the cellular nuclei were stained by Hoescht Nuclear Stain 33342 (Pierce).
Following the HA-LNP-FD or HA-LNP-tagged incubation and subsequent staining
procedure, the cells were washed three times with 1X PBS and visualized with an Inverted
confocal microscope (Olympus IX 81) at the UNL Microscopy Core Research Facility.
3.2.5. Potency Assay
The DOX concentration lethal to 50% of the 21MT-1 cells (LC50) was determined
utilizing the MTT (3-(4,5-dimethyldiazol-2-yl)2,5 diphenyl Tetrazolium Bromide) assay
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kit from Life Technologies (Carlsbad, CA, USA). This classical colorimetric assay assesses
cell health as a function of the mitochondrial conversion of MTT salt to Formazan. 21MT1 cells were seeded at a density of 32,000 cells/well in three 48 well plates with DOX
encapsulated inside HA-LNPs. After a 24 hours incubation time, the media was aspirated
and 5 mg/ml MTT working solution was added and incubated for 2 hours at 37°C. Cells
were then lysed with lysis buffer (acidified IPA) and the absorbance was measured at 570
and 620 nm using a Beckman Coulter AD340 plate reader (Indianapolis, IN, USA). Percent
viability was determined by normalization of the 570/620 ratio to the control untreated
cells and positive control dead cells.
3.2.6. Statistical Analysis
The difference between experimental groups was analyzed by a one-way analysis of
variance (ANOVA) in the software package Prism 6 (Graphpad) and by a subsequent
Tukey’s multiple comparison test. For statistical analysis of all data, p<0.05 was taken as
the lowest acceptable threshold for significance.

3.3. Results and Discussion
3.1.1. Naked vs HA-LNP encapsulated uptake of FD
To test the ability of the HA-LNP nanocarrier system to encapsulate and delivery a
range of therapeutic cargo, we employed the use of the model drug FITC-Dextran. FITCDextran (FD) is a hydrophilic cargo that is 1) cell membrane impermeable, 2) fluorescently
tagged, and 3) can be synthesized to a range of molecular weights to model the delivery of
different size therapeutics. For cell uptake experiments we specifically chose 20kDa and
70 kDa FD. 20kDa FD is the size of most silencing RNAs for gene delivery applications,
where 70 kDa FD is the size of most protein based therapeutics. To address the broad need
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for nanoparticle systems as well as to discern the overall efficacy of the HA-LNP platform,
we performed cell uptake experiments with heart, breast, and brain cells in vitro.
Cardiovascular disease effects an estimated 84 million Americans, causing on average
2,200 deaths per day, and an annual economic cost of over $300 billion dollars in both
health expenditures and lost productivity [43]. Novel nanoparticle systems are needed to
alleviate this health epidemic via improved delivery of cardiovascular therapeutics. To test
our HA-LNP system on cardiac cells, we first incubated HL1 cardiomyocytes with 70 pmol
FD (20 kDa or 70 kDa) in either the “naked” (non nanocarrier) form or with an equivalent
amount of FD encapsulated inside HA-LNPs (HA-LNP-FD) and compared the uptake
qualitatively using a fluorescent microscope and quantitatively using a plate reader (Fig
3.1). After a five hour incubation, we observed very low uptake of naked FD and
significantly more uptake with the HA-LNP system for both 20 and 70 kDa FD. We also
observed higher fluorescent intensity in the HA-LNP- 70 kDa FD sample over the HALNP- 20 kDa FD sample due to the higher density of FITC tagging on the longer chain
dextran. Overall this experiment validated the successful encapsulation and uptake of a cell
impermeable cargo mediated by the HA-LNP system to cardiovascular cells.
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Figure 3. 1. Analysis of the cardiomyocyte (HL1) uptake of 20 and 70 kDa FD model
drug in vitro. The model drug was utilized in two distinct forms: 1) encapsulated inside
the aqueous core of HA-LNPs and 2) naked (no association with a nanocarrier). Plate
reader quantification five hours post addition of the naked FD or HA-LNP-FD (*P<0.05,
**P<0.005, ***P<0.0001; n=3).

We next performed the analogous FD uptake procedure on breast cell lines in vitro.
Breast cancer is the second leading cause of death for women in the United States with
current projections for 2015 forecasting over 230,000 newly diagnosed invasive cases and
40,000 resultant deaths [44]. Consequently, it is extremely important to be able to
successfully delivery a range of therapeutic drugs into breast cells. Three developmentally
distinct human breast cell lines were chosen for nanoparticle uptake analysis: 1) MCF10A
(normal mammary epithelial cells), 2) SKBR3 (HER2+ invasive breast cancer cells), and
3) 21MT-1 (stable patient-derived metastatic breast cancer cells isolated from the
metastatic pleural effusion) (Fig 3.2). We observed that the fluorescence intensity was
significantly higher in all three cell types when FD was delivered using HA-LNPs as
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compared to naked delivery. Furthermore, the metastatic cell line had the highest
fluorescence intensity compared to other cell lines indicating that the uptake of the LNPs
was highest in the metastatic cells. This experiment signified that there was a strong
correlation between uptake of the HA-LNP-FD particles and the degree of the breast tissue
malignancy.

A

B

Figure 3. 2. Analysis of the cellular uptake of FD model drug to human breast cell lines
in vitro. The model drug was utilized in two distinct forms: 1) encapsulated inside the
aqueous core of HA-LNPs and 2) naked (no association with a nanocarrier). Plate reader
quantification five hours post addition of the naked FD or HA-LNP-FD. (A) 20 kDa; (B)
70 kDa (*P<0.05, **P<0.005, ***P<0.0001; n=3).
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To validate the fluorescent intensity via the HA-LNP system was intracellular and not
due to FD residing on the outer cell membrane as a result of the adhesive nature of
liposomes, we also performed live confocal microscopy with the 21MT-1 cell line
following incubation with HA-LNP-20kDa FD (Fig 3.3) and HA-LNP-70 kDa (Fig 3.4).
This experiment clearly demonstrated the intracellular delivery of both 20 kDa and 70 kDa
FD with the HA-LNP system.

Figure 3. 3. Live confocal microscopy was used to validate the intracellular delivery of the
20kDa FD cargo from the HA-LNP-FD nanocarrier: A cluster of 21MT-1 breast cancer
cells at 100x magnification with optical zoom (Scale bars are 5µm).

26

Figure 3. 4. Live confocal microscopy was used to validate the intracellular delivery of
the 70kDa FD cargo from the HA-LNP-FD nanocarrier: A cluster of 21MT-1 breast
cancer cells at 100x magnification with optical zoom (Scale bars are 10µm).

The last disease model we addressed in this study is Glioblastoma. Glioblastoma is an
aggressive brain tumor arising from astrocytes that occurs in 12 to 15 percent of all
intracranial tumors and has a mean survival of 14.6 months [45]. Recently, liposomes and
lipid based nanocarrier systems have gained attention as a promising tool for drug
delivery through the blood brain barrier [12, 46]. However, there still remains a need for
further development in this area to achieve a platform capable of long term glioblastoma
disease management. To test our HA-LNP platform for therapeutic delivery to the brain,
we used flow cytometry to compare the per cell uptake of our HA-LNPs. In this
experiment we tagged our HA-LNPs with 0.15 mass % fluorescent conjugated
cholesterol and incubated an analogous concentration of nanoparticles to two different
brain cell types: 1) rat primary cerebellum astrocytes and 2) A172- a human glioblastoma
cell line. Five hours after nanoparticle addition, we quantified the fluorescent uptake in a
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per cell basis and observed a preferential uptake of particles to the glioblastoma cells over
the primary cerebellum astrocytes (Fig 3.5). In addition to metabolic effects altering the
cellular endocytosis rate, we are currently investigating the difference in surface receptors
between the brain cells to determine the difference in cellular uptake.

Figure 3. 5 Analysis of the cellular uptake of fluorescently conjugated HA-LNPs to
primary rat cerebellum astrocytes and a human glioblastoma cell line (A172). The
fluorescent HA-LNPs were added, and analyzed for per cell fluorescent intensity via flow
cytometry five hours post addition (*P<0.05, **P<0.005, ***P<0.0001; n=3).

3.1.2. Potency Assay with DOX
Following validation that the HA-LNP carrier can be used for model therapeutic
delivery into cardiac, breast, and brain cells in vitro, we next wanted to determine the
efficacy of the HA-LNP to deliver a bioactive drug to probe the true therapeutic benefit of
the HA-LNP system. Doxorubicin (DOX) is a commonly employed chemotherapeutic
anticancer drug with natural fluorescent properties. To determine the efficacy of delivering
encapsulated chemotherapeutics within the LNP nanocarrier, we performed a potency
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assay between free DOX and HA-LNP-DOX with the 21MT-1 metastatic breast cancer
cell line (Fig 3.6).

Figure 3. 6. Doxorubicin potency assay comparison between Free Dox and DOX
encapsulated in HALNPs (HA-LNP-DOX). Standard MTT protocol was used to determine
the % viable cells at 24 hours.

The potency assay exposed that the lowest lethal concentration to kill 50% of the cells
(LC50) was 0.191±0.030 µg/ml and 0.136±0.025 µg/ml for free DOX and HA-LNP-DOX
respectively (Table 3.1). This data shows that a 30% increase in therapeutic index of DOX
was achieve via intracellular delivery in HA-LNPs. As a control, a potency assay with
empty HA-LNPs (no DOX) was performed. We observed no toxicity at lipid levels 100
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times higher than the concentrations used in the DOX potency assay, thus demonstrating
that the lipid nanocarrier is an efficient and non-toxic delivery system (Fig 3.7).
Table 3. 1. Potency assay summary (LC50 values) between the free
form DOX, and HA-LNP encapsulated DOX to 21MT-1
Metastatic Breast Cancer Cells at 24 hrs.

Figure 3. 7. LC50 nonlinear regression curves with both confidence and prediction bands
for the 24 hr. potency assay comparison between the HA-LNP- DOX and free form DOX
in 21MT-1 metastatic breast cancer cells.
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3.1.3. Endolysosomal Tracking of Fluorescently Tagged HA-LNPs
For the successful implementation of the HA-LNP system for drug delivery
applications, the nanocarrier itself must evade lysosomal degradation so the therapeutic
cargo can escape to the cytosol to perform its intended function. To probe the
endolysosomal fate of the HA-LNP system, we utilized our green fluorescent cholesterol
tagged HA-LNPs and performed live confocal microscopy. We first plated 21MT-1 cells,
incubated the cells with tagged HA-LNPs, stained cellular lysosomes (a main degradation
pathway for nanoparticles) red, and found minimal co-localization between the lysosomes
and our HA-LNPs (Fig 3.8A). In addition, we found that our HA-LNPs were
homogenously dispersed in the cellular cytoplasm, signifying endosomal escape. In order
to validate that the HA-LNPs were cytosolic, we performed a z-axis transformation to
construct a side profile view of the cells (XZ plane view: the bottom of the XZ plane is the
contact point between the cells and the petri dish) (Fig 3.8B). We used the nucleus as an
internal reference point in this construct to validate the nanoparticles were in fact cytosolic
and not residing on the outer cellular membrane. In this z-axis transformation analysis the
HA-LNPs also appeared uniform in dispersion with virtually no co-localization with
lysosomes.
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B

Figure 3. 8. Live confocal microscopy analysis of HA-LNP localization in the 21MT-1
metastatic breast cancer cell line in vitro. HA-LNPs with 0.15 mass % FITC tagged
cholesterol in the lipid bilayer of the nanoparticles was used to track nanoparticle endocytosis into the cell. (A) The cholesterol tagged HA-LNPs were incubated with the
21MT-1 cells for 5 hours and measured for co-localization with lysosomes to determine
the fraction of viable therapeutic that escapes the nanoparticle degradation pathway. (B)
Confocal Microscopy with a Z-axis transformation of 21MT-1 cells at 100x zoom was
used to validate cytoplasmic delivery by using the nucleus as a reference point inside the
cell (The XZ plan shows the height and width of the cell).
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We also performed the tagged HA-LNP incubation and confocal microscopy analysis
with cardiomyocytes cells to probe cell-dependent endolysosomal fate (Fig. 3.9). A much
higher amount of co-localization occurred between the HA-LNPs and the lysosomes in
the cardiac cells, signifying more lysosomal entrapment and subsequent HA-LNP
degradation. This may be due to the increased lyosomal activity of this cell type over the
metastatic breast cancer cell line, or the change in the endocytosis pathway used by the
HA-LNPs.

Figure 3. 9. Live confocal microscopy analysis of HA-LNP localization in the HL-1
mouse cardiomyocyte cell line in vitro. HA-LNPs with 0.15 mass % FITC tagged
cholesterol in the lipid bilayer of the nanoparticles was used to track nanoparticle endocytosis into the cell. The cholesterol tagged HA-LNPs were incubated with the HL-1
cells for 5 hours and measured for co-localization with lysosomes to determine the
fraction of viable therapeutic that escapes the nanoparticle degradation pathway.

Lastly, we compared the endolysosomal fate of primary cerebellum astrocytes and
glioblastoma cells (Fig 3.10). This experiment exposed a very high uptake of HA-LNPs
into the glioblastoma cells, with minimal co-localization with lysosomes albeit high
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lysosomal activity present in the cell (Fig 3.10 A). However the uptake of HA-LNPs in
primary cerebellum astrocytes was significantly lower, and expressed higher lyosomal
entrapment. These HA-LNP uptake results match the flow cytometry output achieved
earlier.

A

B

Figure 3. 10. Live confocal microscopy analysis of HA-LNP localization in brain cells in
vitro. HA-LNPs with 0.15 mass % FITC tagged cholesterol in the lipid bilayer of the
nanoparticles was used to track nanoparticle - endocytosis into the cell. The cholesterol
tagged HA-LNPs were incubated with the (A) A172 human glioblastoma cell line or (B)
Primary rat cerebellum astrocytes for 5 hours and measured for co-localization with
lysosomes to determine the fraction of viable therapeutic that escapes the nanoparticle
degradation pathway.
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3.4. Conclusions
The efficacy and ultimate employment of a nanocarrier system for disease
management is dependent upon the successful intracellular delivery of a therapeutic
cargo. In this study, the HA-LNP system was shown to facilitate uptake of a cell
impermeable fluorescent model cargo, FITC-dextran. Furthermore, the HA-LNP system
increased the therapeutic index of Doxorubicin by over 30 % compared to the free form
of the drug to metastatic breast cancer cells. Lastly, confocal microscopy was used to
probe the endolysomal fate of HA-LNPs in cardiac, brain, and breast cells leading to
validation of cell-dependent cytoplasmic distributions of the nanocarrier system.
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CHAPTER 4: EFFECT OF SUBSTRATE STIFFNESS ON
LIPID NANOPARTICLE UPTAKE
4.1. Introduction
The mechanics of the cellular microenvironment such as physical cues from the
extracellular matrix (ECM) greatly influence cellular processes such as proliferation,
migration, and differentiation [47]. Furthermore, the transition of epithelial cells from
healthy to a malignant phenotype has been shown to be accompanied with structural
changes in the local ECM leading to increased stiffness [48] , hindered diffusion [49, 50],
and deregulated ECM expression and dynamics [51, 52]. As a result of this transition,
the efficacy of chemotherapeutics for the treatment of cancerous tumors has been shown
to be reduced [53]. To date, multiple nanocarrier systems and novel methods have been
developed to not only circumvent, but to harness the diffusional constraints of tumor sites
for targeting purposes [54]. However, the direct relationship between the local ECM
stiffness effect on cells and nanoparticle uptake has not been thoroughly investigated.
Tumor tissues have been observed to exhibit stage specific stiffness profiles during
malignancy progression [48]. If the ECM plays a central role in cellular processing, it
would make sense that changes in ECM stiffness effects nanoparticle uptake. Although
numerous studies have been performed analyzing specific attributes of nanoparticles that
effect uptake efficiency, there is a need to better understand how changes in the
mechanics of the cellular microenvironment effects nanoparticle uptake.
Herein we utilized a highly tunable dual polymer system to create an array of 2D gel
substrates with stiffness ranging from 2 kPa to 70 kPa. We employed the 21MT-1
metastatic breast cancer cell line due to its ability to mimic in vivo cancer development
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and behavior within the in vitro enviroment in a stage dependent manner. We utilized our
previously engineered and optimized hyaluronic acid coated lipid nanoparticles (HALNPs) to validate that both the stiffness range chosen was able to significantly alter the
phenotype of the 21MT-1 cells and that the HA-LNPs were able to achieve homogenous
cytoplasmic distribution in cells cultured on varying stiffness. Furthermore, we directly
probed nanoparitcle uptake as a function of susbtrate stiffness at multiple times points via
per cell and population wide flow cytometry analysis.

4.2. Materials and Methods
4.2.1. PDMS Gel fabrication
To create the polymer substrates of varying stiffness, Sylgard 527 and Sylgard 184
(both from Dow Corning) were mixed in specific mass ratios following a previously
reported procedure [55]. The 184:527 mixtures were combined, thoroughly mixed to a
single consistent solution, and added to designated tissue culture dishes. The polymer
gels were then cured overnight at 65°C to facilitate crosslinking. For cell culture
experiments, the gels were activated in an oxygen plasma cleaner to induce a net negative
surface charge, and surface coated with fibronectin (Sigma) to promote cell adhesion.
The polymer containing plates were then UV sterilized for over twelve hours in a
biosafety cabinet.
4.2.2. Gel Stiffness Characterization
In order to measure the stiffness of PDMS substrates, the PDMS precursors Sylgard
527 and Sylgard 184 were directly mixed in the required weight ratio in the multiwell
culture plates followed by overnight crosslinking. Measurement of Young’s Modulus was
carried out using TMS-Pro texture analyzer (Food Technology Corporation, Sterling,
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VA). The height and diameter of the PDMS discs were measured using a caliper. The
samples were compressed 0.2mm and the force and corresponding displacement were
recorded and used to construct stress-strain curves. Young’s Modulus values were
determined from the linear regions of the stress-strain curve.

4.3. Results and Discussion
4.3.1. Polymer Substrate Characterization
To probe the effect of substrate stiffness on lipid nanoparticle (LNP) uptake, we first
fabricated and characterized our polymer gel substrates. The substrates were made from a
specific ratio of sylgard 184 and sylgard 527 polymers following a previously established
protocol [55]. The substrates were cured overnight at 65 °C, allowed to cool to room
temperature, and characterized by young’s modulus measurements (Fig.4.1). We
specifically created four different polymer substrates with stiffness ranging from 2 kPa
(healthy tissue) to 70 kPa (stiffer than high grade invasive ductal carcinoma) [56] to
model the stage dependent cancer progression effects on the tumor microenvironment for
breast tissue.
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Figure 4. 1. Young’s Modulus as a function of percent sylgard 184 polymer. This figure
shows the tunability of the sylgard polymers to create and range of specific stiffness 2D
gel substrates. The inserted table is the stiffness measurements for the four specific
polymer substrates chosen: 2kPa, 12 kPa, 28 kPa, and 70 kPa (n=3).

4.3.2. Cell Morphology changes as a function of substrate stiffness
Following characterization, the polymer substrates were plasma treated to activate the
surface, coated with fibronectin to facilitate cell adhesion, and UV sterilized overnight.
The next day, 21MT-1 cells were seeded on the substrates and allowed to attach and grow
for 24 hours. We specifically chose 21MT-1 cells due to recent reports highlighting the
21T cell line’s ability to mimic in vivo cancer development and behavior within the in
vitro enviroment through stage specific cell proliferation, migration, morpholgy,
polarization, and gene expression profiles, and its consequent potential for usage as a
valuable translational disease model for breast cancer [57].
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In order to assess changes in morphology of the 21MT-1 cells following attatchment
to the different stiffnes substrates, we employed our previously optimized fluorescently
tagged HA-LNP nanocarrier system followed by confocal microscopy analysis (Fig 4.2).
We have previously shown the efficent uptake and homgenous cytoplasmic distribution
of HA-LNPs into 21MT-1 cells on standard tissue culture petri dishes. Therefore, we
utilized our fluorescently tagged HA-LNPs to highlight the difference in cell morphology
on the different stiffness substrates.

Figure 4. 2. 21MT-1 metastatic breast cancer cells morphology depends on substrate
stiffness. Confocal microscopy of fixed 21MT-1 cells atop (A) 2kpA, (B) 12.5 kPa, (C)
28 kPa, and (D) 70 kPa for 24 hours, followed by incubation with fluorescently tagged
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HA-LNPs (green signal) for six hours. The blue is from the Hoescht nuclear stain. The
scale bar is 50μm.

Confocal microscopy analysis of the 21MT-1 cells six hours after HA-LNP addition
revealed a drastic change in cellular morphology between the soft to stiff substrates. On
the soft 2 kPa substrate, the cells exhibited a spherical morphology indicative of a low
stress environment. However, as the substrate stiffness increased, the cell elongation also
increased. This phenomena has been seen in various other cell systems on varying
stiffness substrates [47, 55, 58]. This experiment validated the phenotypical changes of
the 21MT-1 cells as a function of stiffness, as well as the cytoplasmic delivery of the HALNPs on the different 2D gel substrates.
4.3.3. Nanoparticle uptake as a function of stiffness
To directly probe the effect of substrate stiffness on LNP uptake, we incubated a
constant amount of fluorescently tagged HA-LNPs with 21MT-1 cells on each of the 2,
12.5, 28, and 70 kPa stiff polymer substrates. Flow cytometry was then performed to
discern the stiffness effect on nanoparticle intracellular uptake at both 6 and 12 hours post
addition of the HA-LNPs (Fig 4.3).
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A

B

Figure 4. 3. Flow Cytometry analysis of fluorescently conjugated HA-LNP uptake as a
function of substrate stiffness: (A) Per cell fluorescent analysis and (B) % percent
population FITC positive (*P<0.05, **P<0.005, ***P<0.0001; n=3, # denotes
significance between the 2kPa and the sample marked following the same significance
level designations as the stars).
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Interestingly, at the six hour time point an inverse correlation between substrate
stiffness and amount of nanoparticle uptake (per cell fluorescence) was observed. The
soft substrate exhibited significantly higher HA-LNP as compared to the other stiffer
substrate systems. We hypothesize that may be a result of either the reduction in the cell
membrane tension of the cells on the soft substrate mediating the higher amount of
internalized HA-LNPs [59], or a change in the endocytosis route of the HA-LNPs on
different stiffness substrates. However, this preferential uptake mechanisms appears to be
quenched at later time points. At the twelve hour time point, all four of the different
substrate systems exhibited the same degree of HA-LNP uptake per cell.
A similar outcome was also observed for the analysis of the percent 21MT-1
population FITC positive (i.e. the percent population that has internalized the HA-LNP
particles) (Fig 4.3 B). At the six hour time point, cells on the 2 kPa and 12.5 kPa
substrates exhibited significantly broader HA-LNP uptake as compare to the stiffer 28
and 70 kPa. However, at the twelve hour time point, the percent population FITC positive
was actually highest for the stiffest substrate.
The results from this stiffness-nanoparticle uptake experiment are very important
in designing next generation drug delivery systems. The data clearly demonstrates a
transient preferential mechanism in which 21MT-1 cells on soft substrates have an initial
accelerated nanoparticle uptake both per cell and across the entire cell population, but the
overall capacity for HA-LNP uptake between all the substrates is equivalent and matched
at the twelve hour time point. This initial enhanced uptake to cells on soft substrates
should be further examined to determine if the mechanism is cell dependent or cell
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independent phenomena. This information can ultimately be used to develop novel drug
delivery systems capable of increased specificity and rate of intracellular delivery.

4.4. Conclusions
The ECM undergoes dramatic structural and mechanical changes during tumor
progression resulting in altered local stiffness and diffusion patterns. While these changes
in diffusion have been thoroughly investigated and taken into consideration in the
development of drug delivery systems, the effect of stiffness on nanoparticle uptake in
cells is not currently clear. In this study, we used a polymer system to create four
physiologically relevant 2D substrates with stiffness ranging from 2kPa to 70 kPa. We
first delivered our fluorescently conjugated HA-LNPs to 21MT-1 cells cultured on the
polymer substrates of varying stiffness and performed confocal microscopy to validate 1)
homogenous cytoplasmic distribution of the HA-LNPs and 2) the morphology of the cells
was affected by substrate stiffness indicating phenotypical changes. We then probed the
direct effect of substrate stiffness on nanoparticle uptake, and found an initial preferential
uptake of HA-LNPs to cells on soft substrates both per cell and population wide.
However, at later time points we found that the overall capacity for HA-LNP uptake
between all the substrates is equivalent, signifying the effect of HA-LNP is transient.
Further analysis of this mechanism could lead to the development of future drug delivery
platforms with increased intracellular delivery efficiency and specificity.
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CHAPTER 5: FUTURE WORKS
5.1. Targeted Nonviral Gene Delivery in vitro and in vivo
Recently, liposomes and lipid-based nanoparticles have gained attention as a
promising tool for advanced drug delivery to various coordinates of the body including
hard to access regions such as the brain [12, 46]. Liposomes, also referred to as vesicles,
are extremely versatile carriers that have been studied and utilized extensively for drug
delivery applications due to their ease of creation, large protective hydrophilic inner
cavity for encapsulation, high degree of freedom for exterior customization, and
controllable drug release kinetics. Several preclinical studies using drug-encapsulated
liposomes have shown improvement in the sustained release of the cargo, prolonging of
the drug’s half-life and increasing the therapeutic index of corresponding drug [60]. In
addition, numerous drug formulations built on a lipid based platform are currently on the
market including Ambisome [17], Doxil [11] and Epaxal [18] with many more in clinical
development [61, 62]. These examples of proven success alleviate any questions
regarding the clinical viability of liposomal or lipid based platforms as a translational
delivery vehicle for gene delivery. The combination of developing targeted delivery
mechanisms with the labeling of important biomarkers has advanced in vivo application
of lipid based carriers by optimizing drug dosage and reducing off-target effects/resultant
toxicity. For example, antibody surface modified liposomes were used for targeted
siRNA delivery and they successfully silenced genes in leukocytes and reversed
experimentally induced colitis in mice while their naked counterparts (not encapsulated
in liposome) provided no therapeutic value [63]. While previous research has been
performed in the field of silencing RNA gene regulation and its use as an intervention
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tool in disease diagnosis and prevention, there have been minimal proposed lipid based
delivery platforms for gene delivery.

5.2. Substrate Mediated Drug and Gene Delivery System
The engineering of drug delivery platforms facilitating spatial and temporal release of
a therapeutic is one of the key challenges in biomedical research that can ultimately lead
to society-wide improvement in disease management. In recent years, substrate mediated
delivery of cargo has shown great promise in applications including drug and gene
eluding films/scaffolds,[64-67] coatings for stents,[68, 69] and other implantable
devices,[70, 71] and controlling stem cell differentiation.[72] Specifically, the drug
delivery kinetics is particularly relevant when it is necessary to achieve effective dose
and spatiotemporal release kinetics of the therapeutic agent at the intended site of injury.
Delivery via immobilization of the therapeutic cargo to a solid platform demonstrates
higher translatable success compared to delivery using the free “bolus” form by
overcoming unfavorable burst kinetics, toxic offsite effects, and efficacy reduction due to
systemic dilution. This cargo confinement mechanism to the substrate platform have been
engineered via ionic[73], chemical[74] , and physical means[75, 76] to achieve controlled
spatial organization, while cargo release has been catalyzed by changes in local pH,
temperature, and material-intrinsic shifts (ex. swelling and hydrolysis driven degradation)
to acquire specific temporal release profiles.[77] Although considerable progress has
been made, there is a lack in the development of a substrate-mediated delivery system
capable of simultaneous controlled and truly localized delivery of therapeutics.
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5.3. Lipid Nanoparticle Biodistribution Analysis in vivo as a function
of HA Length
In 2015 nearly 1,600 deaths will occur daily in the US as a result of cancer or cancer
related complications, and over 1,665,540 Americans will be diagnosed with invasive
cancer [44]. Depending on the specific type/ stage of cancer, traditional treatment options
include chemotherapy, radiation therapy, hormone therapy, and biological therapy [44,
78]. These treatment measures are invasive, induce an array of adverse side effects, or
only work until the body develops a specific resistance. The use of advanced drug
delivery systems (ADDS) to transport chemotherapeutics specifically to cancer cells
preferentially over normal cells is a relatively new treatment option for cancer patients,
and has yielded massive attention and subsequent capital and intellectual investment. The
ability for an ADDS to transport cargo with variable solubility and unfavorable
pharmacokinetics while exhibiting cargo protection, controlled release, and targeting
capabilities is the ultimate goal in order to decrease variability in systemic concentration
and therefore require less overall dosage during treatment [78, 79]. By definition, drug
delivery systems are engineered technologies such as nanoparticles, virus-based
nanocarriers, etc. created to aid and mediate the delivery of a therapeutic agent [79].
ADDS utilize targeted delivery mechanisms to deliver cargo to specific coordinates of the
body by either a passive process such as the Enhanced Permeability and Retention effect
(EPR) exhibited in tumors due to leaky vasculature, or an active process such as specific
ligand interactions. Since their discovery in the 1960s, lipid based nanoparticles (LNPs)
have been at the forefront of drug delivery due to their biocompatibility, modifiable
surface characteristics, and ease of creation [21]. Surface crosslinking of LNPs with
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extracellular matrix (ECM) proteins such as Hyaluronic Acid has been shown to provide
a hydrophilic barrier against opsonization in vivo, while also exhibiting dual functionality
as a targeting moiety for selective active transport [28, 30].
Hyaluronic Acid (HA) is a main component of the ECM whose molecular weight
(MW) has been shown to dictate its function and overall role in vivo: low MW HA plays
a role in cellular signaling and is known to stimulate angiogenesis and the innate immune
response, while high MW HA plays a structural role for cells and is known to be
relatively inert in cell signaling [80]. For ADDS applications, HA has begun to draw
attention for its ability to specifically bind and promote endocytosis inside various cancer
cells that overexpress CD44 surface receptor [81]. CD44 is a glycoprotein receptor that
is involved in pathological conditions including tumor growth/ metastasis, and has been
shown to increase in cell surface expression during the progression of oncogenesis,
yielding a preferential binding domain for HA conjugated LNPs [82]. Both in vitro and in
vivo models have validated that the affinity of the interaction between HA and CD44
directly correlates to the MW of the HA polymer [13, 83]. However, a current lack in the
understanding of how the MW and surface coating density of HA on LNP surfaces
affects uptake and accumulation in the liver during systemic administration in vivo is
hindering progress in the usage of such conjugate LNP platforms. The interaction
between the HA- LNPs and both the Kupffer cells (KCs) and Liver Sinusoidal
Endothelial Cells (LSECs) of the liver needs to be probed to determine optimum
conditions for systemic delivery to reduce hepatotoxicity and increase accumulation in
the target tumor site. This research will lead to an improved strategy to deliver cargo
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including chemotherapeutics, silencing RNA, DNA, etc. for the treatment of a variety of
cancer models.
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